Biomerica Inc 8-K, filed Oct 15, 2026
Biomerica Inc (BMRA)
About this 8-K
Biomerica Inc filed this 8-K on October 15, 2026, reporting on events of October 9, 2026.
Biomerica Inc. reported that David Moatazedi will not stand for re-election at the December 11, 2026 Annual Meeting; his departure was not due to any dispute or disagreement with the company or Board. AI summary
Items reported
- Item 5.02: Director or officer change, or executive pay
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s
telephone number, including area code:
Not Applicable
(Former name or former address if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of each exchange on which registered | ||
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On October 12, 2026, David Moatazedi, a member of the Board of Directors (the “Board”) of Biomerica, Inc. (the “Company”), communicated to the Board that he has determined not to stand for re-election to the Board at the Company’s 2026 Annual Meeting of the Stockholders, which is set for December 11, 2026. Mr. Moatazedi serves on the Nominating and Corporate Governance Committee and the Audit Committee of the Board and as Chairperson of the Compensation Committee of the Board. Mr. Moatazedi’s decision not to stand for re-election was not the result of any dispute or disagreement with the Company or the Board. Mr. Moatazedi has served on the Board since December 2022. The Company thanks Mr. Moatazedi for his dedicated service to the Company.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| BIOMERICA, INC. | ||
| Date: October 15, 2026 | By: | /s/ Zackary S. Irani |
Zackary S. Irani | ||
| Chief Executive Officer | ||